Seaport Therapeutics

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Sensorium Therapeutics

This biotech company develops central nervous system therapies for patients with anxiety, epilepsy and neurodegenerative diseases using a machine learning drug discovery platform.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Rapport Therapeutics

This company develops small molecule precision medicines for patients suffering from central nervous system disorders.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.